A PYMNTS Company

EU: Boehringer gains conditional okay to buy Sanofi

By  |  November 9, 2016

German drugmaker Boehringer Ingelheim won EU antitrust approval on Wednesday to acquire French peer Sanofi’s Merial animal health business after agreeing to sell some of Merial’s vaccines and pharmaceuticals to allay competition concerns.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The companies unveiled a $20 billion asset swap in December last year, under which Sanofi would buy Boehringer’s consumer health division, and the German firm purchase Merial.

    The European Commission said the concessions from Boehringer allayed worries that the deal would harm competition and possibly result in price hikes.

    “The two companies offered to divest a number of Merial’s marketed and pipeline products, including its existing vaccines Circovac, Progressis, Parvovax, Parvovurax and Mucossifa and pharmaceuticals Ketofen, Wellicox, Allevinix, Genixine, Equioxx Injectable and Equioxx Paste,” the EU enforcer said.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.